Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. National Cancer Institute Nci Usa

Evaluate

Thumbnail
March 03, 2022

Karyopharm kicks the Xpovio can to an uncertain 2024

Thumbnail
December 07, 2020

Ash 2020 – US academics target the Car-T relapse problem

Article image
Vantage logo
November 27, 2020

Danyelza validates a flotation and an anticancer mechanism

Article image
Vantage logo
May 28, 2020

Asco 2020 – Keytruda a “new standard” in biomarker-driven cancer

The Merck & Co drug looks to extend its position in a biomarker-defined colorectal cancer niche, but is it too early to declare victory?

Article image
Vantage logo
August 28, 2019

Immatics and Adaptimmune show that T-cell receptor deals aren't dead

Article image
Vantage logo
August 09, 2019

Upcoming events – United seeks a Distinct hit, and Biogen nears a rare catalyst

A low-key lung cancer readout approaches for United Therapeutics’ Unituxin, while Biogen hopes to buck the tau trend.

Article image
Vantage logo
June 12, 2019

Ziopharm stakes its reputation on personalised cell therapy

Article image
Vantage logo
April 01, 2019

AACR 2019 – Entinostat turns Syndax’s frown upside down

After two checkpoint combo trials flopped last month Syndax celebrates an unexpected win in a third.

Article image
Vantage logo
March 31, 2019

AACR 2019 – Baylor sets the benchmark for Bellicum

A Baylor College study suggests to investors what Bellicum’s upcoming first-in-human trial of BPX-603 will have to match.

Article image
Vantage logo
March 19, 2019

Celyad spells out its off-the-shelf ambitions

Article image
Vantage logo
March 14, 2019

Bellicum pins its next cell therapy hope on Her2

  • Load More
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 17, 2023

PD(L)anner – February 2023

February 09, 2023

Biopharma and Medtech Review 2022

View more...

Editor's Picks

Vantage logo
March 13, 2023

Silicon Valley Bank: biopharma’s latest crisis

Vantage logo
March 13, 2023

Pfizer rescues biotech

Vantage logo
February 28, 2023

Why Pfizer (and others) will be interested in Seagen

Vantage logo
March 04, 2023

ACC 2023 – Esperion’s outcomes win looks lacklustre

Vantage logo
March 06, 2023

T-cell receptor behemoths consolidate? Not quite

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-80-1164-4754

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy
  • Modern Slavery Statement

© Copyright 2023 Evaluate Ltd.

Sign up